The second, a pre-clinical study in the mdx mouse model for DMD, conducted using a mouse specific second generation CD49d ASO (ISIS 348574) to show that monotherapy treatment can reduce CD49d mRNA expression in muscle and decrease contraction induced muscle damage. Here, ITGA4 is linked to Duchenne muscular dystrophy.